Sale to Vectura Group
Our Frankfurt, London, and New York attorneys advised the shareholders of Activaero GmbH, Gmünden in the sale of all their shares to Vectura Group plc for a total of €130 million, funded through a combination of cash payments and Vectura shares.
Activaero is a private German pharmaceutical company originating from Helmholtz Zentrum München and providing novel solutions for severe respiratory diseases. Vectura is a UK-based product development company, listed on the London Stock Exchange (LSE: VEC), which focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases. The acquisition of Activaero fulfills a number of strategic priorities for Vectura in a single transaction, including making the company a therapeutic area specialist for airways diseases.